The Narcolepsy drugs in development market research report provides comprehensive information on the therapeutics under development for Narcolepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Narcolepsy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Narcolepsy and features dormant and discontinued products.
GlobalData tracks 35 drugs in development for Narcolepsy by 25 companies/universities/institutes. The top development phase for Narcolepsy is phase i with 11 drugs in that stage. The Narcolepsy pipeline has 34 drugs in development by companies and one by universities/ institutes. Some of the companies in the Narcolepsy pipeline products market are: Takeda Pharmaceutical, NLS Pharmaceutics and Bioprojet SCR.
The key targets in the Narcolepsy pipeline products market include Orexin Receptor Type 2, Sodium Dependent Dopamine Transporter, and Histamine H3 Receptor.
The key mechanisms of action in the Narcolepsy pipeline product include Orexin Receptor Type 2 Agonist with 14 drugs in Phase III. The Narcolepsy pipeline products include three routes of administration with the top ROA being Oral and two key molecule types in the Narcolepsy pipeline products market including Small Molecule, and Peptide.
Narcolepsy overview
Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations, and sleep paralysis. Narcolepsy treatment includes lifestyle changes, medication, and counseling.
For a complete picture of Narcolepsy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
